These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17101096)

  • 1. [mTOR inhibitors: pleiotropic antiproliferative drugs].
    Pallet N; Beaune P; Thervet E; Legendre C; Anglicheau D
    Med Sci (Paris); 2006 Nov; 22(11):947-52. PubMed ID: 17101096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rapamycine and mTOR inhibitors: from bench to bedside].
    Pallet N; Beaune P; Legendre C; Anglicheau D
    Ann Biol Clin (Paris); 2006; 64(2):107-15. PubMed ID: 16556521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ; Abraham RT; Yu K
    Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR-what does it do?
    Hall MN
    Transplant Proc; 2008 Dec; 40(10 Suppl):S5-8. PubMed ID: 19100909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [mTOR, the mammalian target of rapamycin].
    Julien LA; Roux PP
    Med Sci (Paris); 2010 Dec; 26(12):1056-60. PubMed ID: 21187044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
    Mounier N; Vignot S; Spano JP
    Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M; Rowinsky EK
    Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitors in hematologic malignancies.
    Dancey JE
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):419-23. PubMed ID: 16258427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
    Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
    Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis.
    Seeliger H; Guba M; Kleespies A; Jauch KW; Bruns CJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):611-21. PubMed ID: 17713840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mammalian target of rapamycin pathway and its role in molecular nutrition regulation.
    Lian J; Yan XH; Peng J; Jiang SW
    Mol Nutr Food Res; 2008 Apr; 52(4):393-9. PubMed ID: 18306429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumoral effect of proliferation signal inhibitors].
    Dumortier J
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S263-7. PubMed ID: 20004333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the mammalian target of rapamycin (mTOR) in renal disease.
    Lieberthal W; Levine JS
    J Am Soc Nephrol; 2009 Dec; 20(12):2493-502. PubMed ID: 19875810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring mammalian target of rapamycin (mTOR) activity.
    Ikenoue T; Hong S; Inoki K
    Methods Enzymol; 2009; 452():165-80. PubMed ID: 19200882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.
    Fingar DC; Blenis J
    Oncogene; 2004 Apr; 23(18):3151-71. PubMed ID: 15094765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.